Scarica l'app Stockscreener
77.25
4.65%
3.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
BridgeBio’s receives EU approval for its Transthyretin Amyloidosis treatment - MSN
Discipline and Rules-Based Execution in BBIO Response - Stock Traders Daily
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears - Yahoo Finance
Can BridgeBio Pharma Inc. stock hit record highs againJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - ulpravda.ru
Why BridgeBio Pharma Inc. stock could rally in 2025Quarterly Market Summary & High Yield Stock Recommendations - ulpravda.ru
How BridgeBio Pharma Inc. stock compares to industry benchmarksQuarterly Profit Review & Free Long-Term Investment Growth Plans - ulpravda.ru
Is BridgeBio Pharma Inc. stock a bargain at current levels2025 Risk Factors & Weekly High Return Forecasts - ulpravda.ru
How BridgeBio Pharma Inc. stock reacts to oil prices2025 Pullback Review & Fast Entry Momentum Trade Alerts - ulpravda.ru
BBIO: Truist Securities Raises Price Target to $86, Maintains Bu - GuruFocus
Will BridgeBio Pharma Inc. stock benefit from green energy trendsCPI Data & Fast Entry Momentum Trade Alerts - ulpravda.ru
Intratumoral Cancer Therapies Market Expected to Reach US$ - openPR.com
Is BridgeBio Pharma (BBIO) Pricing Reflect Long Term Potential After 156.5% One Year Surge - Yahoo Finance
BBIO's Analyst Rating: Morgan Stanley Initiates Coverage with Ov - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Morgan Stanley - MarketBeat
BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says - MarketScreener
Morgan Stanley Initiates BridgeBio Pharma at Overweight With $96 Price Target - MarketScreener
Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating By Investing.com - Investing.com Canada
Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating - Investing.com India
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 6.5%Should You Sell? - MarketBeat
BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms - TechStock²
BridgeBio to Participate in the J.P. Morgan Healthcare Conference - The Manila Times
BridgeBio Pharma stock hits all-time high at 78.46 USD By Investing.com - Investing.com Nigeria
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month HighHere's What Happened - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.46 USD - Investing.com
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET - The Manila Times
BridgeBio Pharma to Host Investor Webinar on Infigratinib and Achondroplasia Treatment Developments - Quiver Quantitative
Moody Aldrich Partners LLC Has $3.72 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc.Common Stock (NQ: BBIO - FinancialContent
BridgeBio Pharma Earnings Notes - Trefis
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Behavioral Patterns of BBIO and Institutional Flows - Stock Traders Daily
Corient Private Wealth LLC Acquires New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Aug Chart Watch: How BridgeBio Pharma Inc stock compares to industry benchmarksWeekly Trend Summary & Precise Trade Entry Recommendations - moha.gov.vn
BridgeBio Has More Room To Run (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma stock hits all-time high at $77.32 By Investing.com - Investing.com Nigeria
BridgeBio Pharma stock hits all-time high at $77.32 - Investing.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assenagon Asset Management S.A. Trims Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Why global investors buy BridgeBio Pharma Inc. (2CL) stockJuly 2025 Fed Impact & Low Risk Entry Point Guides - Улправда
Will BridgeBio Pharma Inc. stock benefit from commodity pricesTrade Entry Report & Real-Time Sentiment Analysis - Улправда
First Week of August 2026 Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
What hedge fund activity signals for BridgeBio Pharma Inc. stock2025 Big Picture & Reliable Entry Point Trade Alerts - Улправда
Gains Recap: Why BridgeBio Pharma Inc. stock could rally in 2025Analyst Upgrade & Weekly Top Stock Performers List - Улправда
Will BridgeBio Pharma Inc. stock maintain growth story2025 Market Trends & Low Risk Growth Stock Ideas - Улправда
BridgeBio Pharma Sees Unusually Large Options Volume (NASDAQ:BBIO) - MarketBeat
Layoff Watch: What hedge fund activity signals for BridgeBio Pharma Inc. stockJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Path To Profitability - 富途牛牛
Hypoparathyroidism Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 30,011 Shares - MarketBeat
Pres Trimarchi Acquires 11,174 Of Bridgebio Pharma Inc [BBIO] - TradingView — Track All Markets
BridgeBio Pharma (BBIO) CEO discloses RSU vesting and stock sales - Stock Titan
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):